Patents by Inventor Tyler Curiel

Tyler Curiel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATING AND PREVENTING MELANOMA WITH S-EQUOL
    Publication number: 20220387380
    Abstract: The present invention provides methods and compositions for treating or preventing melanoma with S-equol. The S-equol may be administered alone or in combination with one or more cytotoxic or immunotherapeutic compound or molecule.
    Type: Application
    Filed: August 15, 2022
    Publication date: December 8, 2022
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Rong LI, Bin YUAN, Tyler CURIEL
  • METHODS OF TREATING AND PREVENTING BREAST CANCER WITH S-EQUOL
    Publication number: 20210338632
    Abstract: The present invention provides methods and compositions for treating or preventing breast cancer with S-equol. The method and compositions are particularly suited to treating triple-negative breast cancer. The S-equol may be administered alone or in combination with one or more cytotoxic or immunotherapeutic compound or molecule.
    Type: Application
    Filed: July 9, 2021
    Publication date: November 4, 2021
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Rong Li, Bin Yuan, Tyler Curiel
  • Methods of treating and preventing breast cancer with S-equol
    Patent number: 11090286
    Abstract: The present invention provides methods and compositions for treating or preventing breast cancer with S-equol. The method and compositions are particularly suited to treating triple-negative breast cancer. The S-equol may be administered alone or in combination with one or more cytotoxic or immunotherapeutic compound or molecule.
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: August 17, 2021
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Rong Li, Bin Yuan, Tyler Curiel
  • METHODS OF TREATING AND PREVENTING MELANOMA WITH S-EQUOL
    Publication number: 20190380998
    Abstract: The present invention provides methods and compositions for treating or preventing melanoma with S-equol. The S-equol may be administered alone or in combination with one or more cytotoxic or immunotherapeutic compound or molecule.
    Type: Application
    Filed: April 15, 2019
    Publication date: December 19, 2019
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Rong LI, Bin YUAN, Tyler CURIEL
  • METHODS OF TREATING AND PREVENTING BREAST CANCER WITH S-EQUOL
    Publication number: 20190380997
    Abstract: The present invention provides methods and compositions for treating or preventing breast cancer with S-equol. The method and compositions are particularly suited to treating triple-negative breast cancer. The S-equol may be administered alone or in combination with one or more cytotoxic or immunotherapeutic compound or molecule.
    Type: Application
    Filed: April 15, 2019
    Publication date: December 19, 2019
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Rong LI, Bin LI, Tyler CURIEL
  • Inhibition of intracellular replication by pyridinylimidazoles
    Patent number: 6649637
    Abstract: Substituted pyridinylimidazoles SB203580 and SB202190 strongly inhibit replication and cause stage conversion from active tachyzoites to relatively dormant bradyzoites of the medically important, obligate intracellular parasite Toxoplasma gondii. The pyridinylimidazoles probably mediate these effects by acting on a presently unidentified homologue(s) of human p38-mitogen activated protein kinase present in the tachyzoites. SB203580 also significantly enhanced in vitro inhibition of T. gondii replication by the approved anti-Toxoplasma drug pyrimethamine. The pyridinylimidazoles and related compounds disclosed herein could thus be significant adjuncts to currently available therapies.
    Type: Grant
    Filed: March 15, 2002
    Date of Patent: November 18, 2003
    Inventor: Tyler Curiel
  • Inhibition of Toxoplasma gondii replication by pyridinylimidazoles
    Publication number: 20020132843
    Abstract: Substituted pyridinylimidazoles SB203580 and SB202190 strongly inhibit replication and cause stage conversion from active tachyzoites to relatively dormant bradyzoites of the medically important, obligate intracellular parasite Toxoplasma gondii. The pyridinylimidazoles probably mediate these effects by acting on a presently unidentified homologue(s) of human p38-mitogen activated protein kinase present in the tachyzoites. SB203580 also significantly enhanced in vitro inhibition of T. gondii replication by the approved anti-Toxoplasma drug pyrimethamine. The pyridinylimidazoles and related compounds disclosed herein could thus be significant adjuncts to currently available therapies.
    Type: Application
    Filed: March 15, 2002
    Publication date: September 19, 2002
    Inventor: Tyler Curiel